This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wyse, D. G. Search for Related Content PubMed PubMed Citation Articles by Wyse, D. G. Related Collections Cardiovascular Pharmacology Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2006;114:1670-1672.)
© 2006 American Heart Association, Inc.

Editorial

Transvenous Radiofrequency Catheter Ablation for Atrial Flutter and Atrial Fibrillation

The End of the Beginning?

D. George Wyse, MD, PhD

From the Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary/Calgary Health Region, Calgary, Alberta, Canada.

Correspondence to Dr D. George Wyse, Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary/Calgary Health Region, Room G009, Health Sciences Center, 3350 Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1. E-mail dgwyse@ucalgary.ca

Key Words: Editorials • ablation • antiarrhythmia agents • arrhythmia • atrial flutter • randomized controlled trials

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 

Now this is not the end. It is not even the beginning of the end, but it is, perhaps the end of the beginning.

—Winston Churchill, November 10, 1942

Transvenous radiofrequency catheter ablation (RFA) for treatment of atrioventricular (AV) reentrant tachycardia and AV nodal reentrant tachycardia is remarkably successful. To the best of my knowledge, there has not been a large randomized trial comparing RFA with other treatments for these tachycardias. The lack of such trials is due at least in part to the self-evident efficacy of RFA in this setting. In turn, the efficacy of RFA for these tachycardias is in large part due to the fact that the anatomy and pathophysiology of these two tachycardias are well understood. The success of RFA for treating AV reentrant tachycardia and AV nodal reentrant tachycardia has quite rightly led to a large effort to expand this success, and thereby the indications for RFA, to other tachyarrhythmias.

Article p 1676

Among the supraventricular tachyarrhythmias, the atrial flutter (AFL)/atrial fibrillation (AF) family is an obvious but challenging target for RFA. The early results are promising. AF is numerically the largest member of this family of tachyarrhythmias. The other family members are atrial tachycardia and AFL. These tachyarrhythmias can be closely related anatomically, can share a common pathophysiology, and can be found in the same patient.¹

There are probably several different anatomies and pathophysiologies for these tachyarrhythmias. Inability to fully understand the anatomy and pathophysiology of a tachyarrhythmia in an individual patient makes RFA . . . [Full Text of this Article]

This article has been cited by other articles:

				Catheter Ablation vs. Amiodarone for First Atrial Flutter in Elders Journal Watch Cardiology, November 14, 2006; 2006(1114): 4 - 4. [Full Text]